Bipolar disorder market across 7MM set to grow at 5.3% CAGR between 2024 and 2034, forecasts GlobalData

New Delhi: The bipolar disorder (BD) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is poised to grow at a compound annual growth rate (CAGR) of 5.3% from $5.6 billion in 2024 to $9.4 billion in 2034, forecasts GlobalData, a leading data and analytics company.

GlobalData’s report, “Bipolar Disorder – Opportunity Assessment and Forecast,” reveals that growth will primarily be driven by an increase in diagnosed prevalence as well as the introduction of six late-stage pipeline products: Azetukalner, Bysanti (milsaperidone), Cyclurad (cycloserine + lurasidone), NRX-100 (ketamine hydrochloride), endoxifen, and Cobenfy (trospium chloride + xanomeline).

Of the six late-stage pipeline agents, four of them—Cyclurad (cycloserine + lurasidone), NRX-100 (ketamine hydrochloride), Bysanti (milsaperidone), and azetukalner—are being trialed in patients exhibiting symptoms of bipolar depression

Jos Opdenakker, Neurology Analyst at GlobalData, comments: “This signals a shift in the treatment paradigm towards therapies targeting bipolar depression. Currently, there is a significant unmet need for treatments targeting bipolar depression. This is despite the plethora of mood stabilizers and atypical antipsychotics available for bipolar disorder, which usually target manic or mixed states and do not specifically target the depressive polarity of the disorder.”

GlobalData forecasts that the late-stage pipeline products could drive combined sales of approximately $2.8 billion by 2034 in the 7MM.

GlobalData also anticipates that the most promising pipeline product will be Bristol-Myers Squibb’s Cobenfy (trospium chloride + xanomeline), which is currently being trialed in manic episodes associated with bipolar I disorder. It has the potential to see strong uptake due to its established efficacy in treating schizophrenia and its novel mechanism of action, leveraging cholinergic modulation beyond the traditional dopamine antagonism shared by most currently available atypical antipsychotics.

Opdenakker concludes: “Although the BD market is dominated by cheap generics that will act as a major barrier to growth, late-stage pipeline products have potential to generate significant growth in the BD market. This, coupled with the increase in diagnosed prevalent cases, will act as the main drivers of growth across the 7MM.”